Dr. William McCulloch President

Dr. William McCulloch (Bill) practiced medicine for seven years in the U.K., including post- graduate training in Internal Medicine, Hematology and Oncology, before joining the international pharmaceutical industry in 1984. Since then, his career as a senior R&D executive in a variety of large and small companies has afforded him extensive experience in developing and commercializing technologies. His areas of responsibility have included non-clinical and clinical development, regulatory and medical affairs, licensing and sales force training, with a focus in oncology and serious infectious diseases. He has undertaken all phases of drug and technology development, and has been directly involved in filing INDs and NDAs, securing Orphan Drug status for compounds and obtaining SBIR and other grant funding for his projects.

In 2002, Bill co-founded Alba BioPharm Advisors, and as president and medical consultant he has provided a wide variety of consulting services for the company's small, mid-sized and large pharma clients.   Bill has acted as medical advisor for Gloucester Pharmaceuticals from 2003 to the present, and served as Executive Vice President and Chief Medical Officer from 2004-2007.  During this  period he provided the medical expertise which was instrumental in the acquisition, clinical development and ultimate FDA approval of the company's anticancer agent, romidepsin (Istodax).  Since Gloucester's acquisition by Celgene Corporation in December 2009, he has continued to provide services to the company as a senior medical advisor.  Before co-founding Alba BioPharm Advisors, Bill served as Executive Vice President & Medical Director of A.M. Pappas & Associates, LLC, a North Carolina life sciences venture development firm. From 1997 until 2002 he developed and managed the company’s international pharmaceutical and biotechnology advisory practice, with clients ranging from large pharmaceutical firms to start-up companies. In addition, he provided due diligence and other services in support of the company’s significant venture capital activities. Previous U.S. appointments have included Senior Vice President of R&D for Sparta Pharmaceuticals (1992–97), and Vice President of Clinical R&D for U.S. Bioscience (1988-92). While residing in Europe, he held senior executive positions with Bristol-Myers Co., Celltech Ltd., and Astra Alab, a division of Astra AB (now Astra Zeneca). Bill earned his M.B., Ch.B. (M.D. equivalent) from the University of Glasgow in Scotland, is a Member of the Royal College of Physicians (UK), Fellow of the Royal College of Physicians (Glasgow) and Fellow of the Faculty of Pharmaceutical Medicine, UK. In addition, he holds a Diploma from the Royal College of Obstetricians and Gynaecologists, UK. He is a member of the American Society of Clinical Oncology.

Dr. Margaret McCulloch

Dr. Margaret McCulloch studied medicine in her native Scotland, receiving her MB ChB (MD equivalent) from Glasgow University in 1977. She is a Fellow of the Royal College of Anesthetists, London, and a Fellow of the Royal College of Physicians and Surgeons (Glasgow). She completed her post-graduate training in anesthesiology in Scotland, and subsequently practiced for 12 years in Scotland, England and Sweden before moving to the USA.  Margaret returned to the combined world of medicine and business in 2002 by co-founding Alba BioPharm Advisors, Inc. along with her husband, Bill.  Her core client services included pharmacovigilance, medical monitoring and assistance with document review and medical writing. Margaret served between 2003 and 2016 as consultant associate medical director with Drug Safety Alliance, a mid-sized pharmacovigilance CRO in Durham, NC .